Health In Tech Reports Second Quarter 2026 Financial Results
Health In Tech (Nasdaq: HIT) reported Q2 2026 revenue of $8.1M versus $9.3M in Q2 2025, and first-half 2026 revenue of $16.8M versus $17.3M. Contracted revenue was $32.3M as of June 30, 2026, and pipeline revenue was $66.3M as of July 31, 2026. Net loss was $2.5M. The company reaffirmed 2026 revenue guidance of $45M to $50M.
How this was made
The 30-second read
Why it matters
The company’s Q2 and first-half results include a reaffirmed 2026 revenue outlook and a quantified pipeline conversion framework that translates quoting/binding status into expected contracted and GAAP revenue in 2026 and 2027.
Market read
Traders can use the reaffirmed guidance and the pipeline conversion math to reassess forward revenue recognition and the credibility of the company’s growth engine.
What to watch
Contracted Revenue recognition timing (GAAP straight-line over policy terms) can create quarter-to-quarter GAAP noise, so traders may overreact to GAAP revenue while underweighting contracted-book growth and PPPV trends.
Background
Health In Tech is an AI-enabled InsurTech platform focused on self-funded health plan stop-loss quoting and placement, using metrics like Contracted Revenue and Pipeline Revenue to describe forward revenue visibility.
Ticker impact
Health In Tech reported Q2 2026 revenue of $8.1M, reaffirmed 2026 revenue guidance of $45M to $50M, and detailed pipeline conversion assumptions.
Likely modest post-release volatility, with upside bias if investors focus on pipeline conversion math and contracted-book growth, downside if they fixate on revenue decline and widening losses.
This is a company-specific financial results PR with explicit guidance and forward revenue recognition ranges tied to pipeline conversion (15% to 40%). However, the article does not include consensus comparisons or a new guidance change, and revenue/losses show deterioration versus prior-year periods.
Market effects
Adds datapoints on AI-enabled InsurTech underwriting distribution metrics (brokers/TPAs/agency growth, contracted vs pipeline revenue) that may influence how investors underwrite similar platform models.
No clear regional spillover beyond US-listed InsurTech sentiment.
Limited global relevance; primarily affects US small-cap growth/InsurTech risk appetite.
Counterpoint
Investors may discount the pipeline-to-contracted conversion range as optimistic, given Q2 revenue declined year over year and Adjusted EBITDA remains negative.
Key entities
- companyHealth In Tech, Inc.
Nasdaq-listed AI-enabled InsurTech platform reporting Q2 2026 results, pipeline metrics, and reaffirmed 2026 revenue guidance.
- personTim Johnson
CEO who discussed contracted-book growth, a three-year rate stabilization program milestone, and the planned HitRix marketplace launch in 2H 2026.
